Novo's Ozempic Pill Fails to Slow Alzheimer's in Studies

Watch Novo's Ozempic Pill Fails to Slow Alzheimer's in Studies - Bloomberg on Dailymotion

Transcript

00:00Novo Nordisk's pill version of Ozempic has failed to slow Alzheimer's disease in a pair of large

00:05studies. Despite being a long shot, the shares are plummeting down nearly 10% on the news.

00:11Joining us now is Bloomberg senior health care reporter Naomi Kresge. Naomi, how important was

00:16this for Novo in order to get results that showed that it was improving on the fight against

00:21Alzheimer's in order for them to improve against the fight with Eli Lilly and their market dominance?

00:26Yeah, so I mean, we've seen a massive share plunge on this today, and I think that it's really down

00:35to two reasons. The first is that this trial was, many investors saw it as Novo's way to show some

00:44differentiation in the short term, like Novo's way to kind of come out of the doldrums in the short

00:49term, and that did not happen in this study. It was a failure. And the second is that often,

00:53you know, in a study like this, pharma will point, if there's a failure, they might point to some

00:59subgroup or some small thing in the study that showed some signs of being beneficial. And there

01:08really wasn't any language like that in the statement today. They were very straightforward

01:13about it having not worked, and they're in fact going to halt an extension of the study and just

01:20stop the trial.